Skip to content
OpenCapital
Get started

Theravance Biopharma TBPH Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
——
Royalty Pharma logo
Royalty PharmaRPRX
——
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$896.51M+68.7%
Enterprise value$648.91M+38.3%
P/E7.8×—
P/S8.2×0.0×

Profitability

See full
Gross margin60.8%—
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's available for sale securities debt securities current?
Theravance Biopharma (TBPH) reported available for sale securities debt securities current of $106.57M in Q1 2026.
How has Theravance Biopharma's available for sale securities debt securities current changed year-over-year?
Theravance Biopharma's available for sale securities debt securities current increased by 426.5% year-over-year, from $20.24M to $106.57M.
What is the long-term trend for Theravance Biopharma's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Theravance Biopharma's available for sale securities debt securities current has grown at a -6.9% compound annual growth rate (CAGR), from $211.47M to $147.55M.